IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a previously announced prospectus offering of convertible unsecured subordinated debentures for gross proceeds of more than $6.8-million.Read More
Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs.Read More
Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million.
Each unit consists of one common share and one-half of a warrant at a price of six cents a unit. Each whole warrant entitles the holder to acquire one common share of Avivagen at a price of nine cents for two years from closing.Read More
GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital.
The company also has executed a term sheet with Alumina Partners for a second tranche, allowing GeneNews to draw down on $10-million (US) in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period.Read More